MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a worldwide leader in specialized, study-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative goods, nowadays announced it will provide cannabis concentrate goods in Denmark to two new health-related cannabis prospects below two separate white-label agreements. These prospects will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ very first provide agreements for the export of completed goods to Denmark.
Denmark granted sufferers legal access to cannabis-primarily based medicinal goods two years ago as element of a 4-year pilot system. The system supplies sufferers with protected solution access and national well being authorities with patient information that they can use to fully grasp usage and efficacy. According to data complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred sufferers (mostly females amongst the ages of 42-64) received cannabis-primarily based medicinal goods from 429 prescribing physicians below this system in 2019.
“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis market place for medicinal, wellness and adult use applications and these agreements represent one more step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related market place with new and revolutionary health-related cannabis focused goods positions us for more development in Europe and adds to MediPharm Labs all-crucial physique of information that we are leveraging to improve the design and style of our formulations for sufferers and shoppers everywhere.”
Beneath the agreements, a single which has an initial two-year term and the second a a single-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil goods that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its prospects to commence in October 2020, pending regulatory approval by applicable well being authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured numerous pretty desirable domestic and international provide agreements with higher high-quality partners, now which includes new prospects in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new enterprise wins are a clear and crucial validation of our choice to develop a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs expanding profile and reputation. We appear forward to ramping up production below all of these agreements.”
MediPharm Labs Australia received its Very good Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May well 2020, which enables it to sell cannabis APIs and completed goods to nations across the EU, which includes Denmark. The Organization entered into its very first European white-label cannabis provide agreement that exact same month with Therismos Restricted.
About Denmark’s Health-related Cannabis Market place
Denmark launched its 4-year health-related cannabis pilot system on January 1st, 20181. Post-harvest Very good Manufacturing Processes (GMP) is needed for distribution of health-related cannabis goods in Denmarktwo.
By means of the system, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 locations: discomfort brought on by several sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy remedy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an comprehensive assessment of literature as nicely as assessments of: cannabis schemes in the Netherlands, Canada and Israel preceding cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative goods using a Very good Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an professional, study-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 major extraction lines for delivery of pure, trusted and precision -dosed cannabis goods for its prospects. By means of its wholesale and white label platforms, they formulate, customer-test, procedure, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based goods to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure
Supply: https://www.financialbuzz.com/breaking-news-medipharm-labs-enters-denmark-health-related-cannabis-market place-secures-new-white-label-provide-prospects/